thymine has been researched along with Nausea in 6 studies
Nausea: An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study aimed to clarify the tolerability of a trifluridine/tipiracil combination tablet (TAS-102) in patients with advanced or recurrent colorectal cancer over 75 years of age." | 7.91 | Evaluation of Tolerability of Trifluridine/Tipiracil Combination Tablet in Patients With Advanced/Recurrent Colorectal Cancer. ( Kimura, M; Teramachi, H; Usami, E; Yoshimura, T, 2019) |
| "A novel oral agent that consists of trifluridine and tipiracil hydrochloride (TFTD) has been established as salvage-line treatment for metastatic colorectal cancer (mCRC)." | 7.83 | Self-Reported Adherence to Trifluridine and Tipiracil Hydrochloride for Metastatic Colorectal Cancer: A Retrospective Cohort Study. ( Aoyama, T; Hama, T; Inoue, A; Kawakami, K; Machida, Y; Suenaga, M; Sugisaki, T; Sugita, K; Suzuki, K; Takiguchi, T; Yamaguchi, K; Yamaguchi, T; Yokokawa, T, 2016) |
| "Evaluation demonstrated a trend toward thymidine protection of carboplatin-induced treatment-limiting thrombocytopenia." | 5.09 | Phase I trial of intravenous thymidine and carboplatin in patients with advanced cancer. ( Alberti, D; Arzoomanian, RZ; Cohen, JD; Feierabend, C; Jacobson, E; Katschinski, DM; Mehta, M; Olsen, M; Robins, HI; Tiggelaar, CL; Tutsch, K; Wilding, G, 1999) |
| "This study aimed to clarify the tolerability of a trifluridine/tipiracil combination tablet (TAS-102) in patients with advanced or recurrent colorectal cancer over 75 years of age." | 3.91 | Evaluation of Tolerability of Trifluridine/Tipiracil Combination Tablet in Patients With Advanced/Recurrent Colorectal Cancer. ( Kimura, M; Teramachi, H; Usami, E; Yoshimura, T, 2019) |
| "A novel oral agent that consists of trifluridine and tipiracil hydrochloride (TFTD) has been established as salvage-line treatment for metastatic colorectal cancer (mCRC)." | 3.83 | Self-Reported Adherence to Trifluridine and Tipiracil Hydrochloride for Metastatic Colorectal Cancer: A Retrospective Cohort Study. ( Aoyama, T; Hama, T; Inoue, A; Kawakami, K; Machida, Y; Suenaga, M; Sugisaki, T; Sugita, K; Suzuki, K; Takiguchi, T; Yamaguchi, K; Yamaguchi, T; Yokokawa, T, 2016) |
| " Major adverse events were neutropenia, leukopenia, anemia, and nausea." | 2.82 | Effect of food on the pharmacokinetics of TAS-102 and its efficacy and safety in patients with advanced solid tumors. ( Bando, H; Doi, T; Fuse, N; Goto, K; Ito, Y; Kojima, T; Mukai, H; Naito, Y; Ohtsu, A; Yamazaki, T; Yoshino, T, 2016) |
| "The purpose of the current study was to determine the maximum tolerated dose, dose-limiting toxicities, pharmacokinetic profile, and recommended Phase II dose of oral administration of TAS-102, a novel nucleoside formed by the combination of alpha,alpha,alpha-trifluorothymidine (FTD) and a thymidine phosphorylase inhibitor (TPI: 5-chloro-6-(2-iminopyrrolidin-1-yl)methyl-2,4(1H,3H)-pyrimidinedione)." | 2.72 | Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors. ( Abbruzzese, JL; Bogaard, K; Fukushima, M; Hoff, PM; Hong, DS; Kuwata, K; Lassere, Y; Mita, A, 2006) |
| " Adverse events to TAS-102 monotherapy were observed in 22 out of 23 cases (95." | 1.43 | Safety of an oral anticancer agent (trifluridine/tipiracil combination tablet) in patients with advanced and recurrent colorectal cancer. ( Asano, H; Go, M; Ito, D; Iwai, M; Kimura, M; Teramachi, H; Usami, E; Yoshimura, T, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kimura, M | 2 |
| Usami, E | 2 |
| Teramachi, H | 2 |
| Yoshimura, T | 2 |
| Yoshino, T | 1 |
| Kojima, T | 1 |
| Bando, H | 1 |
| Yamazaki, T | 1 |
| Naito, Y | 1 |
| Mukai, H | 1 |
| Fuse, N | 1 |
| Goto, K | 1 |
| Ito, Y | 1 |
| Doi, T | 1 |
| Ohtsu, A | 1 |
| Go, M | 1 |
| Iwai, M | 1 |
| Ito, D | 1 |
| Asano, H | 1 |
| Sugita, K | 1 |
| Kawakami, K | 1 |
| Yokokawa, T | 1 |
| Sugisaki, T | 1 |
| Takiguchi, T | 1 |
| Aoyama, T | 1 |
| Suzuki, K | 1 |
| Suenaga, M | 1 |
| Yamaguchi, K | 1 |
| Inoue, A | 1 |
| Machida, Y | 1 |
| Yamaguchi, T | 1 |
| Hama, T | 1 |
| Hong, DS | 1 |
| Abbruzzese, JL | 1 |
| Bogaard, K | 1 |
| Lassere, Y | 1 |
| Fukushima, M | 1 |
| Mita, A | 1 |
| Kuwata, K | 1 |
| Hoff, PM | 1 |
| Robins, HI | 1 |
| Tutsch, K | 1 |
| Katschinski, DM | 1 |
| Jacobson, E | 1 |
| Mehta, M | 1 |
| Olsen, M | 1 |
| Cohen, JD | 1 |
| Tiggelaar, CL | 1 |
| Arzoomanian, RZ | 1 |
| Alberti, D | 1 |
| Feierabend, C | 1 |
| Wilding, G | 1 |
3 trials available for thymine and Nausea
| Article | Year |
|---|---|
Effect of food on the pharmacokinetics of TAS-102 and its efficacy and safety in patients with advanced solid tumors.
Topics: Aged; Anemia; Antineoplastic Agents; Area Under Curve; Asian People; Biological Availability; Cross- | 2016 |
Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Area Under Curve; Asthenia; Dose-Response | 2006 |
Phase I trial of intravenous thymidine and carboplatin in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Cohort Studies; Drug Administration Schedule; Drug | 1999 |
3 other studies available for thymine and Nausea
| Article | Year |
|---|---|
Evaluation of Tolerability of Trifluridine/Tipiracil Combination Tablet in Patients With Advanced/Recurrent Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Co | 2019 |
Safety of an oral anticancer agent (trifluridine/tipiracil combination tablet) in patients with advanced and recurrent colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Drug Combinations; Female; | 2016 |
Self-Reported Adherence to Trifluridine and Tipiracil Hydrochloride for Metastatic Colorectal Cancer: A Retrospective Cohort Study.
Topics: Abdominal Pain; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot | 2016 |